Exhibit 99.1 PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from ___________ to __________ Commission file number: 001-36199 PULMATRIX, INC. (Exact name of registrant as specified in its charter) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or Delaware 46-1821392 (State or other jurisdiction of incorporation or organization) ☐ TRANSITION REPORT PURSUANT TO SEC ...

Exhibit 99.1 Ondas Holdings Reports First Quarter 2025 Financial Results—On Track for Record Year Q1 Revenue of $4.2 Million Driven by OAS Growth and Global Demand for Autonomous Drone Systems Over 500% Year-over-Year Revenue Growth Reflects Execution on Backlog that has Increased to $16.8 M Driven by Strong Order Momentum; Reaf irms Outlook for at least $25 Million in Revenue for 2025 "Ondas is entering 2025 with strong momentum, led by the outstanding performance of our Ondas Autonomous Systems business u ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36754 EVOFEM BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 20-8527075 (State or other juris ...

S&W Announces Third Quarter Fiscal 2025 Financial Results Longmont, Colorado – May 15, 2025 – S&W Seed Company (Nasdaq: SANW), or S&W, today announced financial results for the three months ended March 31, 2025. Financial Highlights Management Discussion "The strategic actions we have taken during the past year to reposition S&W's focus on our high-value, high-margin sorghum trait technology were clearly beginning to deliver results during the most recent third quarter (January through March 2025) culminati ...

Exhibit 99.1 Odysight.ai Reports Financial Results for The First Quarter of 2025 and Provides Business Update OMER, Israel, May 15, 2025 – Odysight.ai Inc. (NASDAQ: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions, announces its financial results for the three months ended March 31, 2025 and provides a business update. Key highlights Net cash position of approximately $37.2 million as of March 31, 2025. Einav Brenner, Chief Financial Offic ...

Exhibit 99.1 Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling study initiation The FDA advised the Company to submit pivotal Part B trial protocol and associated statistical analysis plan as an amendment to the IND application, eliminating the need for formal end-of-phase meeting and potentially expediting study initiation and registration ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________________to___________________________ Commission File Number: 001-42374 SYNERGY CHC CORP. (Exact name of registrant as specified in its charte ...

"I'm especially proud of how our team responded to market challenges with agility and precision. We reduced operating expenses by over 50%, improved our cost structure, and maintained our commitment to delivering excellence to our customers. Our strategic transition toward sophisticated, high-margin products in both our electric industrial vehicles and hydraulic transmission systems is already delivering impressive results. We believe this momentum is sustainable over the long-term, and it serves as a clear ...

Exhibit 99.1 Evofem Reports First Quarter 2025 Financial Results and Provides Business Update SAN DIEGO, CA, May 15, 2025 — Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter ended March 31, 2025. "Quarterly fluctuations are normal for our business, which is why we focus on driving annual growth," said Saundra Pelletier, Evofem's CEO. "First quarter net sales were soft, as expected, due to the high level of PHEXXI stocking orders in the f ...